Min Zhan1, Rebecca M Doerfler2, Dawei Xie3, Jing Chen4, Hsiang-Yu Chen3, Clarissa J Diamantidis5, Mahboob Rahman6, Ana C Ricardo7, James Sondheimer8, Louise Strauss6, Lee-Ann Wagner2, Matthew R Weir2, Jeffrey C Fink9. 1. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD. 2. Department of Medicine, University of Maryland School of Medicine, Baltimore, MD. 3. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA. 4. Department of Medicine, Tulane University School of Medicine, New Orleans, LA. 5. Department of Medicine, Duke University School of Medicine, Durham, NC. 6. Department of Medicine, Case Western University, Cleveland, OH. 7. Department of Medicine, University of Illinois at Chicago, Chicago, IL. 8. Department of Medicine, Wayne State University School of Medicine, Detroit, MI. 9. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD. Electronic address: jfink@som.umaryland.edu.
Abstract
RATIONALE & OBJECTIVE: Safe analgesic choices are limited in chronic kidney disease (CKD). We conducted a comparative analysis of harm from opioids versus nonsteroidal anti-inflammatory drugs (NSAIDs) in CKD. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 3,939 patients with CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study. EXPOSURES: 30-day analgesic use reported at annual visits. OUTCOMES: A composite outcome of 50% glomerular filtration rate reduction and kidney failure requiring kidney replacement therapy (KRT), as well as the outcomes of kidney failure requiring KRT, hospitalization, and pre-kidney failure death. ANALYTICAL APPROACH: Marginal structural models with time-updated exposures. RESULTS: Participants were followed up for a median of 6.84 years, with 391 (9.9%) and 612 (15.5%) reporting baseline opioid and NSAID use, respectively. Time-updated opioid use was associated with the kidney disease composite outcome, kidney failure with KRT, death (HRs of 1.4 [95% CI, 1.2-1.7], 1.4 [95% CI, 1.1-1.7], and 1.5 [95% CI, 1.2-2.0], respectively), and hospitalization (rate ratio [RR], 1.7; 95% CI, 1.6-1.9) versus opioid nonusers. Similar results were found in an analysis restricted to a subcohort of participants reporting ever using other (nonopioid and non-NSAID) analgesics or tramadol. Time-updated NSAID use was associated with increased risk for the kidney disease composite (HR, 1.2; 95% CI, 1.0-1.5) and hospitalization (RR, 1.1; 95% CI, 1.0-1.3); however, these associations were not significant in the subcohort. The association of NSAID use with the kidney disease composite outcome varied by race, with a significant risk in blacks (HR, 1.3; 95% CI, 1.0-1.7). NSAID use was associated with lower risk for kidney failure with KRT in women and individuals with glomerular filtration rate<45mL/min/1.73m2 (HRs of 0.63 [95% CI, 0.45-0.88] and 0.77 [95% CI, 0.59-0.99], respectively). LIMITATIONS: Limited periods of recall of analgesic use and potential confounding by indication. CONCLUSIONS: Opioid use had a stronger association with adverse events than NSAIDs, with the latter's association with kidney disease outcomes limited to specific subgroups, notably those of black race.
RATIONALE & OBJECTIVE: Safe analgesic choices are limited in chronic kidney disease (CKD). We conducted a comparative analysis of harm from opioids versus nonsteroidal anti-inflammatory drugs (NSAIDs) in CKD. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 3,939 patients with CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study. EXPOSURES: 30-day analgesic use reported at annual visits. OUTCOMES: A composite outcome of 50% glomerular filtration rate reduction and kidney failure requiring kidney replacement therapy (KRT), as well as the outcomes of kidney failure requiring KRT, hospitalization, and pre-kidney failure death. ANALYTICAL APPROACH: Marginal structural models with time-updated exposures. RESULTS:Participants were followed up for a median of 6.84 years, with 391 (9.9%) and 612 (15.5%) reporting baseline opioid and NSAID use, respectively. Time-updated opioid use was associated with the kidney disease composite outcome, kidney failure with KRT, death (HRs of 1.4 [95% CI, 1.2-1.7], 1.4 [95% CI, 1.1-1.7], and 1.5 [95% CI, 1.2-2.0], respectively), and hospitalization (rate ratio [RR], 1.7; 95% CI, 1.6-1.9) versus opioid nonusers. Similar results were found in an analysis restricted to a subcohort of participants reporting ever using other (nonopioid and non-NSAID) analgesics or tramadol. Time-updated NSAID use was associated with increased risk for the kidney disease composite (HR, 1.2; 95% CI, 1.0-1.5) and hospitalization (RR, 1.1; 95% CI, 1.0-1.3); however, these associations were not significant in the subcohort. The association of NSAID use with the kidney disease composite outcome varied by race, with a significant risk in blacks (HR, 1.3; 95% CI, 1.0-1.7). NSAID use was associated with lower risk for kidney failure with KRT in women and individuals with glomerular filtration rate<45mL/min/1.73m2 (HRs of 0.63 [95% CI, 0.45-0.88] and 0.77 [95% CI, 0.59-0.99], respectively). LIMITATIONS: Limited periods of recall of analgesic use and potential confounding by indication. CONCLUSIONS: Opioid use had a stronger association with adverse events than NSAIDs, with the latter's association with kidney disease outcomes limited to specific subgroups, notably those of black race.
Authors: Søren Lund Kristensen; Emil L Fosbøl; Anne-Lise Kamper; Lars Køber; Kristine Hommel; Morten Lamberts; Steen Z Abildstrøm; Thalia M Blicher; Christian Torp-Pedersen; Gunnar H Gislason Journal: Pharmacoepidemiol Drug Saf Date: 2012-02-17 Impact factor: 2.890
Authors: Laura Plantinga; Vanessa Grubbs; Urmimala Sarkar; Chi-Yuan Hsu; Elizabeth Hedgeman; Bruce Robinson; Rajiv Saran; Linda Geiss; Nilka Ríos Burrows; Mark Eberhardt; Neil Powe Journal: Ann Fam Med Date: 2011 Sep-Oct Impact factor: 5.166
Authors: Joseph A Boscarino; Margaret Rukstalis; Stuart N Hoffman; John J Han; Porat M Erlich; Glenn S Gerhard; Walter F Stewart Journal: Addiction Date: 2010-08-16 Impact factor: 6.526
Authors: Aron J Hall; Joseph E Logan; Robin L Toblin; James A Kaplan; James C Kraner; Danae Bixler; Alex E Crosby; Leonard J Paulozzi Journal: JAMA Date: 2008-12-10 Impact factor: 56.272
Authors: Roger Chou; Richard Deyo; Janna Friedly; Andrea Skelly; Robin Hashimoto; Melissa Weimer; Rochelle Fu; Tracy Dana; Paul Kraegel; Jessica Griffin; Sara Grusing; Erika D Brodt Journal: Ann Intern Med Date: 2017-02-14 Impact factor: 25.391
Authors: Jonathan G Amatruda; Ronit Katz; Carmen A Peralta; Michelle M Estrella; Harini Sarathy; Linda F Fried; Anne B Newman; Chirag R Parikh; Joachim H Ix; Mark J Sarnak; Michael G Shlipak Journal: J Am Geriatr Soc Date: 2020-12-10 Impact factor: 5.562
Authors: William C Becker; Michael J Fischer; Daniel G Tobin; Mark B Lockwood; Paul L Kimmel; Laura M Dember; Nwamaka D Eneanya; Manisha Jhamb; Thomas D Nolin Journal: Nat Rev Nephrol Date: 2021-10-07 Impact factor: 28.314
Authors: Rasheeda K Hall; Jacob B Blumenthal; Rebecca M Doerfler; Jing Chen; Clarissa J Diamantidis; Bernard G Jaar; John W Kusek; Krishna Kallem; Mary B Leonard; Sankar D Navaneethan; Daohang Sha; James H Sondheimer; Lee-Ann Wagner; Wei Yang; Min Zhan; Jeffrey C Fink Journal: Am J Kidney Dis Date: 2021-05-23 Impact factor: 11.072
Authors: Carrie E Brintz; Martin D Cheatle; Laura M Dember; Alicia A Heapy; Manisha Jhamb; Amanda J Shallcross; Jennifer L Steel; Paul L Kimmel; Daniel Cukor Journal: Semin Nephrol Date: 2021-01 Impact factor: 4.472
Authors: I Hernanz; A B Larque; L F Quintana; G Espigol-Frigole; G Espinosa; A Adan; M Sainz-de-la-Maza Journal: Am J Ophthalmol Case Rep Date: 2021-04-22
Authors: Mary Hannan; Sajid Ansari; Natalie Meza; Amanda H Anderson; Anand Srivastava; Sushrut Waikar; Jeanne Charleston; Matthew R Weir; Jonathan Taliercio; Edward Horwitz; Milda R Saunders; Katherine Wolfrum; Harold I Feldman; James P Lash; Ana C Ricardo Journal: Clin J Am Soc Nephrol Date: 2020-11-11 Impact factor: 8.237